---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-018892"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:19:11.271062+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Syndax Q1 2022 net loss $37.2M; cash $397.9M; clinical milestones on track for 2023

## Summary
- Net loss $37.2M ($0.63/sh) vs $27.7M ($0.54) in Q1 2021; R&D spend $30.0M vs $21.9M.
- Cash, cash equivalents and short-term investments $397.9M; 59M shares and equivalents outstanding.
- FY2022 guidance: R&D $130-140M, total opex $160-170M; Q2 opex $38-42M.
- Revumenib: AUGMENT-101 enrollment completion expected later 2022; topline data 1H23; combination trials underway.
- Axatilimab: FDA Fast Track for cGVHD; AGAVE-201 topline data 1H23; potential BLA filing 2023.

## SEC filing metadata
- accession: 0001564590-22-018892
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000156459022018892/0001564590-22-018892-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000156459022018892/sndx-8k_20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-018892
- JSON: https://secwatch.observer/filing/0001564590-22-018892.json
- Plain text: https://secwatch.observer/filing/0001564590-22-018892.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.